Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
49 hedge funds and large institutions have $45.6M invested in Enzo Biochem, Inc. in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 7 closing their positions.
4% more capital invested
Capital invested by funds: $43.8M → $45.6M (+$1.85M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 54 → 49 (-5)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
76% less call options, than puts
Call options by funds: $179K | Put options by funds: $740K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$125K |
| 2 |
SDAM
Shulman DeMeo Asset Management
Lake Success,
New York
|
+$37.4K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$36.1K |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$32.7K |
| 5 |
Bank of New York Mellon
New York
|
+$4.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCA
VIEX Capital Advisors
Sunny Isles Beach,
Florida
|
-$489K |
| 2 |
Renaissance Technologies
New York
|
-$257K |
| 3 |
V
Veritable
Wilmington,
Delaware
|
-$206K |
| 4 |
BlackRock
New York
|
-$150K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$133K |
ENZ Hedge Fund Activity: Q3 2022 in Review
49 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2022, worth a combined $45.6M — up 4.2% from $43.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ENZ and 2 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Group One Trading, opening a new position worth an estimated $125K. The largest seller was VIEX Capital Advisors, cutting an estimated $489K.
- 49 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2022, down from 54 in Q2 2022.
- Funds reported $45.6M of Enzo Biochem, Inc. stock for Q3 2022, up 4.2% quarter-over-quarter.
- 2 funds opened new Enzo Biochem, Inc. positions in Q3 2022 and 7 closed out, a net change of -5 holders.
- The largest Enzo Biochem, Inc. buyer in Q3 2022 was Group One Trading, an estimated $125K added.
- The largest Enzo Biochem, Inc. seller in Q3 2022 was VIEX Capital Advisors, an estimated $489K sold.
Based on aggregated 13F filings for Q3 2022.